Structure-based virtual screening, multi-score docking, and molecular dynamics simulation of novel small molecules targeting the epidermal growth factor receptor for potential management of oral squamous cell carcinoma.

In silico pharmacology Pub Date : 2026-09-06 eCollection Date: 2026-01-01 DOI:10.1007/s40203-026-00722-4
Muhammad Bilal Azmi, Tehreem Zia, Uzma Asif, Sheikh Arslan Sehgal, Sadaf Naeem, Shamim A Qureshi, Syed Danish Haseen Ahmed, Fauzia Imtiaz
{"title":"Structure-based virtual screening, multi-score docking, and molecular dynamics simulation of novel small molecules targeting the epidermal growth factor receptor for potential management of oral squamous cell carcinoma.","authors":"Muhammad Bilal Azmi, Tehreem Zia, Uzma Asif, Sheikh Arslan Sehgal, Sadaf Naeem, Shamim A Qureshi, Syed Danish Haseen Ahmed, Fauzia Imtiaz","doi":"10.1007/s40203-026-00722-4","DOIUrl":null,"url":null,"abstract":"<p><p>Oral squamous cell carcinoma (OSCC) is a major global health burden, with epidermal growth factor receptor (EGFR) serving as an important therapeutic target. However, resistance to currently available EGFR inhibitors limits the efficacy of long-term treatment. In this study, a structure-based virtual screening approach was employed using the Mcule database to identify novel small molecules with potential EGFR-inhibitory activity. The top-ranked compounds were subjected to consensus docking using multiple docking platforms and compared with established EGFR inhibitors. The most promising complexes were further evaluated using 500 ns molecular dynamics simulations to investigate their structural stability, conformational flexibility, and binding persistence. ADMET and pharmacokinetic analyses were performed to assess the drug-like and safety profiles. Five lead compounds (C1-C5) demonstrated significant binding affinities toward EGFR, ranging from - 9.9 to - 9.2 kcal/mol, while satisfying the major drug-likeness criteria. Molecular dynamics simulations suggested that C1 and C4 may form relatively stable EGFR-ligand complexes, as supported by stable RMSD convergence and persistent interactions with key active-site residues throughout the simulation period. Trajectory-based interaction analyses further indicated a sustained binding behavior. ADMET profiling predicted favorable oral bioavailability and low predicted toxicity for most compounds, particularly C3 and C5, although a potential risk of cytochrome P450-mediated drug-drug interactions was observed. Overall, the shortlisted compounds exhibited docking and dynamic stability profiles comparable to those of the reference inhibitor Lapatinib. These findings suggest the potential therapeutic relevance of structurally novel EGFR-targeting scaffolds in OSCC and provide a foundation for future experimental validation through in vitro and in vivo studies.</p><p><strong>Graphical abstract: </strong></p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at https://doi.org/10.1007/s40203-026-00722-4.</p>","PeriodicalId":94038,"journal":{"name":"In silico pharmacology","volume":"14 3","pages":"220"},"PeriodicalIF":0.0000,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13547197/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In silico pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40203-026-00722-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Oral squamous cell carcinoma (OSCC) is a major global health burden, with epidermal growth factor receptor (EGFR) serving as an important therapeutic target. However, resistance to currently available EGFR inhibitors limits the efficacy of long-term treatment. In this study, a structure-based virtual screening approach was employed using the Mcule database to identify novel small molecules with potential EGFR-inhibitory activity. The top-ranked compounds were subjected to consensus docking using multiple docking platforms and compared with established EGFR inhibitors. The most promising complexes were further evaluated using 500 ns molecular dynamics simulations to investigate their structural stability, conformational flexibility, and binding persistence. ADMET and pharmacokinetic analyses were performed to assess the drug-like and safety profiles. Five lead compounds (C1-C5) demonstrated significant binding affinities toward EGFR, ranging from - 9.9 to - 9.2 kcal/mol, while satisfying the major drug-likeness criteria. Molecular dynamics simulations suggested that C1 and C4 may form relatively stable EGFR-ligand complexes, as supported by stable RMSD convergence and persistent interactions with key active-site residues throughout the simulation period. Trajectory-based interaction analyses further indicated a sustained binding behavior. ADMET profiling predicted favorable oral bioavailability and low predicted toxicity for most compounds, particularly C3 and C5, although a potential risk of cytochrome P450-mediated drug-drug interactions was observed. Overall, the shortlisted compounds exhibited docking and dynamic stability profiles comparable to those of the reference inhibitor Lapatinib. These findings suggest the potential therapeutic relevance of structurally novel EGFR-targeting scaffolds in OSCC and provide a foundation for future experimental validation through in vitro and in vivo studies.

Graphical abstract:

Supplementary information: The online version contains supplementary material available at https://doi.org/10.1007/s40203-026-00722-4.

基于结构的虚拟筛选、多重评分对接和靶向表皮生长因子受体的新型小分子分子动力学模拟,用于口腔鳞状细胞癌的潜在治疗。
口腔鳞状细胞癌(OSCC)是全球主要的健康负担,表皮生长因子受体(EGFR)是重要的治疗靶点。然而,对目前可用的EGFR抑制剂的耐药性限制了长期治疗的疗效。在本研究中,采用基于结构的虚拟筛选方法,利用Mcule数据库来鉴定具有潜在egfr抑制活性的新型小分子。排名靠前的化合物使用多个对接平台进行共识对接,并与已建立的EGFR抑制剂进行比较。利用500 ns分子动力学模拟进一步评估了最有希望的配合物,以研究它们的结构稳定性、构象灵活性和结合持久性。进行ADMET和药代动力学分析来评估药物样和安全性。5个先导化合物(C1-C5)与EGFR表现出显著的结合亲和力,范围在- 9.9至- 9.2 kcal/mol之间,同时满足主要的药物相似标准。分子动力学模拟表明,C1和C4可能形成相对稳定的egfr配体复合物,这得到了稳定的RMSD收敛和在整个模拟期间与关键活性位点残基持续相互作用的支持。基于轨迹的相互作用分析进一步表明了持续的结合行为。ADMET分析预测大多数化合物(特别是C3和C5)具有良好的口服生物利用度和低毒性,尽管观察到细胞色素p450介导的药物-药物相互作用的潜在风险。总的来说,候选化合物显示出与参考抑制剂拉帕替尼相当的对接和动态稳定性。这些发现表明结构新颖的egfr靶向支架在OSCC中具有潜在的治疗相关性,并为未来通过体外和体内研究进行实验验证奠定了基础。图片摘要:补充信息:在线版本包含补充材料,可在https://doi.org/10.1007/s40203-026-00722-4上获得。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书